Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 340

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 340
---
 2024. Early adoption is permitted. The Company is currently
evaluating the impact of the adoption of this standard on the related disclosures.

NOTE
3: PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid
expenses and other current assets are comprised of the following:

SCHEDULE
OF PREPAID EXPENSE AND OTHER CURRENT ASSETS 

    2024  
    2023 

    For the year ended December 31, 

    2024  
    2023 
  
    Prepaid insurance 
    $506,489  
    $554,097 
  
    Prepaid research and development 
     150,000  
     17,309 
  
    Other prepaid expenses 
     175,088  
     61,750 
  
    Total prepaid expenses and other current assets 
    $831,577  
    $633,156 
  
    Prepaid expenses and other current assets 
    $831,577  
    $633,156 

NOTE
4: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts
payable and other current liabilities are comprised of the following:

SCHEDULE
OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES 

    2024  
    2023 

    For the year ended December 31, 

    2024  
    2023 
  
    Accounts payable 
    $870,229  
    $806,004 
  
    Accrued employee costs 
     1,371,498  
     1,213,054 
  
    Accrued professional fees 
     72,054  
     39,165 
  
    Accrued research and development 
     860,958  
     439,024 
  
    Accrued board fees 
     117,750  
     117,750 
  
    Delaware franchise taxes payable 
     -  
     40,000 
  
    Other accrued expenses 
     17,228  
     17,330 
  
    Total accounts payable and other current liabilities 
    $3,309,717  
    $2,672,327 

NOTE
5: STOCK-BASED COMPENSATION

The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the “